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White matter alterations are present in the majority of patients with Alzheimer’s disease type dementia. However, the spatiotem-
poral pattern of white matter changes preceding dementia symptoms in Alzheimer’s disease remains unclear, largely due to the
inherent diagnostic uncertainty in the preclinical phase and increased risk of confounding age-related vascular disease and stroke in
late-onset Alzheimer’s disease. In early-onset autosomal-dominantly inherited Alzheimer’s disease, participants are destined to
develop dementia, which provides the opportunity to assess brain changes years before the onset of symptoms, and in the absence
of ageing-related vascular disease. Here, we assessed mean diffusivity alterations in the white matter in 64 mutation carriers
compared to 45 non-carrier family non-carriers. Using tract-based spatial statistics, we mapped the interaction of mutation
status by estimated years from symptom onset on mean diffusivity. For major atlas-derived ﬁbre tracts, we determined the earliest
time point at which abnormal mean diffusivity changes in the mutation carriers were detectable. Lastly, we assessed the association
between mean diffusivity and cerebrospinal ﬂuid biomarkers of amyloid, tau, phosphorylated-tau, and soluble TREM2, i.e. a
marker of microglia activity. Results showed a signiﬁcant interaction of mutations status by estimated years from symptom onset,
i.e. a stronger increase of mean diffusivity, within the posterior parietal and medial frontal white matter in mutation carriers
compared with non-carriers. The earliest increase of mean diffusivity was observed in the forceps major, forceps minor and long
projecting ﬁbres—many connecting default mode network regions—between 5 to 10 years before estimated symptom onset. Higher
mean diffusivity in ﬁbre tracts was associated with lower grey matter volume in the tracts’ projection zones. Global mean diffu-
sivity was correlated with lower cerebrospinal ﬂuid levels of amyloid-b1-42 but higher levels of tau, phosphorylated-tau and soluble
TREM2. Together, these results suggest that regionally selective white matter degeneration occurs years before the estimated
symptom onset. Such white matter alterations are associated with primary Alzheimer’s disease pathology and microglia activity
in the brain.
1 Institute for Stroke and Dementia Research, Klinikum der Universita¨t Mu¨nchen, Ludwig-Maximilians-Universita¨t LMU, Munich,
Germany
2 German Center for Neurodegenerative Diseases (DZNE, Munich), Munich, Germany
3 Biomedical Center, Biochemistry, Ludwig-Maximilians-Universita¨t Mu¨nchen, Munich, Germany
4 Department of Radiology, Washington University in St Louis, St Louis, MO, USA
5 Knight Alzheimer’s Disease Research Center, Washington University in St. Louis, St. Louis, MO, USA
doi:10.1093/brain/awy229 BRAIN 2018: Page 1 of 16 | 1
Received February 23, 2018. Revised July 11, 2018. Accepted July 20, 2018.
 The Author(s) (2018). Published by Oxford University Press on behalf of the Guarantors of Brain.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse,
distribution, and reproduction in any medium, provided the original work is properly cited.
D
ow
nloaded from
 https://academ
ic.oup.com
/brain/advance-article-abstract/doi/10.1093/brain/aw
y229/5104289 by C
atherine Sharp user on 21 Septem
ber 2018
6 Hope Center for Neurological Disorders, Washington University in St. Louis, St. Louis, MO, USA
7 Department of Radiology, Mayo Clinic, Rochester, MN, USA
8 Department of Neurology, Ludwig-Maximilians-Universita¨t Mu¨nchen, Munich, Germany
9 Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
10 Hertie Institute for Clinical Brain Research, Tu¨bingen, Germany and German Center for Neurodegenerative Diseases (DZNE),
Tu¨bingen, Germany
11 Department of Psychiatry, Washington University in St Louis, St Louis, MO, USA
12 The Florey Institute, The University of Melbourne, Parkville, Victoria, Australia
13 University of California at San Francisco, San Francisco, CA94143, USA
14 Dementia Research Centre, University College London, Queen Square, London, UK
15 Department of Neurology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
16 Department of Neurology, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA
17 Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA
18 Ronald M. Loeb Center for Alzheimer’s Disease, Department of Neuroscience, Icahn School of Medicine at Mount Sinai,
New York, New York, USA
19 Department of Nuclear Medicine, Technical University of Munich, Munich, Germany
20 Department of Neurology, Washington University in St. Louis, St. Louis, MO, USA
21 Neuroscience Research Australia, Barker Street Randwick, Sydney 2031, Australia
22 School of Medical Sciences, University of New South Wales, Sydney 2052, Australia
Correspondence to: Michael Ewers
Institute for Stroke and Dementia Research, Klinikum der Universita¨t Mu¨nchen, Ludwig-Maximilians-Universita¨t Mu¨nchen,
Feodor-Lynen-Straße D-81377 Munich, Germany
E-mail: Michael.Ewers@med.uni-muenchen.de
Keywords: Alzheimer’s disease; autosomal dominant; white matter; diffusion tensor imaging; TREM2
Abbreviations: DTI = diffusion tensor imaging; EYO = estimated years from symptom onset; PIB = Pittsburgh compound B; PSMD
= peak-width of skeletonized mean diffusivity; TBSS = tract-based spatial statistics; WMH = white matter hyperintensity
Introduction
In Alzheimer’s disease, white matter degeneration is a fre-
quent structural brain change apart from grey matter atro-
phy (Brun and Englund, 1986). Post-mortem studies showed
loss of myelin, axonal degeneration and gliosis in the brains
from patients with Alzheimer’s disease (Brun and Englund,
1986). Such white matter alterations cannot be fully ac-
counted for as degenerative processes secondary to grey
matter damage (Brun and Englund, 1986; Englund, 1998;
Agosta et al., 2011), but may stem from vascular amyloid
deposition and microvascular damage (Weller et al., 2009).
According to the vascular hypothesis, cerebrovascular alter-
ations may contribute to neurodegeneration and white
matter damage by reducing the drainage of amyloid and
increasing the production of amyloid-b (Zlokovic, 2011).
In support of this hypothesis, recent evidence from neuroi-
maging studies suggests that vascular alterations such as
cerebrovascular resistance and hypoperfusion may precede
amyloid deposition and are predictive of future disease pro-
gression (Iturria-Medina et al., 2016; Yew et al., 2017).
Thus, it is possible that vascular and amyloid deposition
are synergistically involved in Alzheimer’s disease and con-
tribute to white matter alterations. Higher levels of white
matter alterations are associated with FDG-PET decline
(Lo et al., 2012; Glodzik et al., 2014; Marnane et al.,
2016), higher grey matter atrophy (Bos et al., 2017), reduced
functional network integrity (Taylor et al., 2017) and worse
cognitive decline (Lo et al., 2012; Marchant et al., 2012;
Vemuri et al., 2015). Thus, white matter alterations, possibly
stemming from cerebrovascular disease, may add to the ef-
fects of amyloid deposition on neurodegeneration and cog-
nition in ageing and Alzheimer’s disease.
A major question is when and where in the brain white
matter alterations occur during the course of Alzheimer’s
disease. So far, biomarker studies demonstrated the succes-
sive development of primary pathologies including amyloid-
b and tau (as measured by bioﬂuid and molecular PET
markers) followed by alterations of medial temporal and
parietal grey matter (as measured by volumetric MRI and
FDG-PET) in both sporadic late-onset Alzheimer’s disease
(Jack et al., 2012) and genetically-caused Alzheimer’s dis-
ease (Bateman et al., 2012). However, the integration of
white matter changes within standard biomarker models
of the pathological cascade in Alzheimer’s disease remains
missing (Jack et al., 2013). The major goal of the current
study was to close this research gap and determine the re-
gional patterns of microstructural white matter alterations
in different stages of Alzheimer’s disease.
White matter alterations can be detected in vivo by dif-
fusion tensor imaging (DTI) (Alexander et al., 2007).
Results from DTI showed that ﬁbre tract alterations are
widespread in the brain at the stage of mild cognitive im-
pairment and Alzheimer’s disease dementia (Bozzali et al.,
2002; Medina et al., 2006; Acosta-Cabronero et al., 2010,
2012; Sexton et al., 2011; Bosch et al., 2012; for reviews
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see Acosta-Cabronero and Nestor, 2014; Teipel et al.,
2015). In particular, major ﬁbre tracts such as the forceps
major and forceps minor, inferior fronto-occipital fascic-
ulus as well as the posterior cingulum show white matter
alterations in Alzheimer’s disease dementia (Taylor et al.,
2001; Teipel et al., 2002; Douaud et al., 2011; Mito et al.,
2018). Those ﬁbre tracts connect regions of the default
mode network (DMN) and their degeneration may thus
contribute to the impairment of the DMN and other func-
tional networks in Alzheimer’s disease (Taylor et al., 2017).
Despite these previous ﬁndings in symptomatic Alzheimer’s
disease participants, white matter changes in the preclinical
phase before the occurrence of cognitive impairment have
been examined only in a few studies (Gold et al., 2012). In
asymptomatic subjects at genetic risk of Alzheimer’s disease
(Bendlin et al., 2010; Gold et al., 2010; Cavedo et al.,
2017) or with abnormal Alzheimer’s disease biomarker
values (Li et al., 2014; Racine et al., 2017), results are
mixed including DTI-assessed white matter alterations pre-
dominantly in the cingulum, corpus callosum and limbic
ﬁbres (Bendlin et al., 2010; Gold et al., 2010; Racine
et al., 2017), but also absence of any DTI changes (Li
et al., 2014). A difﬁculty in the interpretation of these pre-
vious ﬁndings is the uncertain future development of de-
mentia symptoms at the presumed preclinical stage of
Alzheimer’s disease. In contrast, in autosomal-dominant
Alzheimer’s disease mutation carriers will all develop de-
mentia and the future onset of dementia symptoms can be
more precisely estimated (Ryman et al., 2014).
Furthermore, because of the younger age at onset of auto-
somal-dominant Alzheimer’s disease, there is less likelihood
of confounding vascular disease. However, it should be
cautioned that results from autosomal-dominant
Alzheimer’s disease do not necessarily generalize to spor-
adic late-onset Alzheimer’s disease. Age-related vascular
changes may inﬂuence disease progression in late-onset
Alzheimer’s disease, including the development of white
matter alterations (Iturria-Medina et al., 2016), which is
less likely to be captured in autosomal dominant
Alzheimer’s disease where dementia symptoms typically
emerge between 30 and 50 years of age. Nevertheless, neu-
roimaging and biomarker studies show consistencies in the
sequential onset of amyloid deposition, tau, FDG-PET
hypometabolism, grey matter atrophy, and clinical presen-
tation between late-onset and autosomal-dominant
Alzheimer’s disease (Bateman et al., 2012; Benzinger
et al., 2013; Young et al., 2014; Gordon et al., 2018;
Oxtoby et al., 2018), suggesting substantial commonalities
between both sporadic late-onset and genetically caused
Alzheimer’s disease. A few DTI studies on white matter
alterations in autosomal-dominant Alzheimer’s disease
have been previously conducted (Ringman et al., 2007;
Ryan et al., 2013; Parra et al., 2015; Sanchez-Valle et al.,
2016). However, these studies either lacked sufﬁcient stat-
istical power considering the relatively low sample sizes
(n = 8 to 18 of asymptomatic carriers) to detect subtle
pre-symptomatic phase or did not estimate years from
symptom onset (EYO) (Ringman et al., 2007; Ryan et al.,
2013; Parra et al., 2015), which reduced the sensitivity to
detect DTI changes that occur in close proximity to the
onset of dementia symptoms.
In the current study, our primary aim was to map DTI
alterations as a function of EYO and to place the time
course of white matter alterations within the temporal bio-
marker model of Alzheimer’s disease. We controlled for the
inﬂuence of white matter hyperintensities, i.e. macrostruc-
tural white matter changes that can signiﬁcantly alter DTI
measures such as mean diffusivity (Medina et al., 2006). A
secondary aim was to test whether CSF-based biomarker
alterations of Alzheimer’s disease pathology and microglia
activity are related to mean diffusivity alterations. This aim
was motivated by recent ﬁndings of a close relationship be-
tween tau pathology and white matter diffusion alterations
(Sydykova et al., 2007; Kantarci et al., 2017; Jacobs et al.,
2018), as well as alterations of CSF levels of TREM2, a
marker of microglia activity in Alzheimer’s disease
(Kleinberger et al., 2014; Suarez-Calvet et al., 2016a, b).
For all analyses, we used mean diffusivity as our primary
DTI measure in autosomal-dominant Alzheimer’s disease,
since previous studies found mean diffusivity to be the
most sensitive DTI marker to detect ﬁbre tract alterations
(Clerx et al., 2012; Nowrangi et al., 2013).
Materials and methods
Study design
Participants
We included 153 subjects from the Dominantly Inherited
Alzheimer Network (DIAN, data freeze 9). Participants en-
rolled in DIAN were examined on the basis of a comprehen-
sive battery of neuropsychological testing, neuroimaging
assessments and biomarker (CSF) measurements. EYO was
determined based on the age of onset of the parent from
whom they inherited the mutation (Bateman et al., 2012).
The current study is a subset of the 218 participants in
whom we reported previously CSF soluble TREM2 changes
(Suarez-Calvet et al., 2016a). For the current study, additional
inclusion criteria were: availability of DTI scan (n = 42 partici-
pants excluded), and acquisition with 64 diffusion directions
(n = 23 participants excluded). Quality control applied to the
remaining DTI scans resulted in the exclusion of an additional
37 participants because of only partial coverage of the brain
due to a restricted ﬁeld of view. Excluded were also cases with
abnormalities that prevented a valid DTI analysis, including
frontal DTI signal loss (n = 1), intracerebral haemorrhage
(n = 3), severe grey matter atrophy (n = 1), signs of cerebral
amyloid angiopathy (n = 1, number of microbleeds = 100), or
an extremely large white matter hyperintensity volume [n = 1,
25  the interquartile range (IQR) above the median within
the mutation carriers, Tukey criterion of outlier deﬁned as
1.5  IQR]. This ﬁnal sample of n = 109 participants com-
prised 64 carriers and 45 non-carriers (Table 1). Mutations
occurred within the PSEN1 (n = 47), PSEN2 (n = 8), and
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APP (n = 9) genes. Compared to the carriers who were
excluded, those carriers included were slightly younger [mean
(standard deviation, SD) = 38.3 (11.3) versus 41.5 (10.0) years,
P = 0.04] and had a lower EYO [mean (SD) = 9.1 (11.2)
versus 4.6 (9.9) EYO, P = 0.02]. No differences in gender
distribution, APOE genotype or years of education were pre-
sent between the carrier groups, nor were any differences in
those variables detected between included and excluded non-
carriers. The proportion of carriers versus non-carriers was
similar between the ﬁnal sample and the excluded participants
(57.2% versus 61.9%, P = 0.6).
MRI scan acquisition
Whole-brain T1-weighted MPRAGE scans (repetition
time = 2300ms, echo time = 2.95ms, ﬂip angle = 9) with
1.1mm  1.1mm  1.2mm voxel size were acquired.
The DTI scans consisted of whole-brain T2*-echo planar
images (repetition time = 11 000ms, echo time = 87ms). The
acquisition was performed axially with an anterior-to-posterior
phase-encoding direction. One reference volume (b = 0 s/mm2)
and 64 diffusion volumes (b = 1000 s/mm2) with uniformly dis-
tributed diffusion directions were acquired with isotropic
2.5mm voxel size. That standardized DTI protocol was imple-
mented exclusively on 3 T MRI scanners with a 20-channel
head coil from the manufacturer Siemens at 10 centres in
DIAN. Sites were qualiﬁed by phantom and human volunteer
scans, and quality control of scans by a central laboratory
(C.J., Mayo Clinic) was implemented to reduce between-
centre variability that may arise from varying ﬁlters for
image reconstruction, gradient strength and other magnetic
resonance features set by vendor-speciﬁc magnetic resonance
protocols. T2-FLAIR scans were acquired axially (repetition
time = 9000ms, echo time = 91ms, ﬂip angle = 150) with
0.9mm  0.9mm  5.0mm voxel size.
Preprocessing of MRI scans
The DTI scans were corrected for motion, eddy-current and sus-
ceptibility artefacts using a pipeline implemented in ExploreDTI
(http://www.ExploreDTI.com). Brieﬂy, for motion correction,
rigid-body rotations using the b = 0 scan as a reference image
were applied to both the b = 1000 s/mm2 volumes and B-matrix
of diffusion directions (Leemans and Jones, 2009). Eddy-current
correction was performed by afﬁne transformation of the
b = 1000 s/mm2 volumes to the B0 scan. Correction for
susceptibility distortion was performed by non-linear registration
of the diffusion-weighted and B0 scans to the subject’s brain-
extracted T1, using the brain masks as priors and allowing only
for deformations in the phase-encoding direction (Irfanoglu
et al., 2012). After all corrections were performed, the param-
eters of the diffusion tensor were estimated via weighted least-
squares to generate maps of mean diffusivity. Mean diffusivity
was our main DTI-derived quantity of interest, but for explora-
tory analyses we also generated maps of other commonly used
DTI indices including fractional anisotropy, radial diffusivity and
axial diffusivity previously found to be altered in Alzheimer’s
disease (for review see Acosta-Cabronero and Nestor, 2014).
Subsequently, each subject’s maps of the different DTI indices
were projected onto the standard FMRIB-58 fractional anisot-
ropy template in MNI space and skeletonized. This was con-
ducted via the Tract-Based Spatial Statistics (TBSS) toolbox of
FSL (https://fsl.fmrib.ox.ac.uk/fsl/fslwiki), using the implemented
spatial normalization routing and standard parameters (Smith
et al., 2006). We applied a white matter skeleton mask from
the TBSS toolbox, which was modiﬁed such that the fornix
and other regions prone to partial-volume effects were excluded,
as established previously (Baykara et al., 2016).
White matter hyperintensity segmentation
White matter hyperintensities (WMHs) were identiﬁed based
on FLAIR scans, using a semi-automated in-house method
described previously (Taylor et al., 2017). For further details
see the Supplementary material.
Detection of microbleeds and superficial cortical
siderosis
To assess the inﬂuence of cerebral amyloid angiopathy-related
small vessel disease on white matter changes, we rated micro-
bleeds and superﬁcial cortical siderosis. Based on T2*-weighted
gradient echo images, which were available in a subset of sub-
jects (n = 71), microbleeds and superﬁcial cortical siderosis
were assessed via visual inspection by an expert rater
(M.D.). Microbleeds were rated according to the STRIVE con-
sensus criteria (Wardlaw et al., 2013).
Determination of grey matter volume in projection
zones of fibre tracts
In the ﬁrst step, those ﬁbre tracts that contained signiﬁcant
alterations in autosomal-dominant Alzheimer’s disease were
determined. To this end, the Johns Hopkins University
whole-brain tractography atlas (in MNI space) (Wakana
et al., 2007), was superimposed onto the TBSS-derived statis-
tical map of the EYO  mutation interaction effect (see also
‘Statistical analyses’ section below). Some tracts showed no or
only a small number of signiﬁcant voxels (0.8–1.6% of the
total voxel-number per tract) and were excluded from further
analysis. This resulted in a set of 8 of 11 ﬁbre tracts. In add-
ition, we a priori included the hippocampal cingulum bundle
ﬁbre tract on the basis of previous publications showing early
alterations of this tract in Alzheimer’s disease (Zhang et al.,
2009; Jacobs et al., 2018).
Next, we determined the grey matter projection zones of
those selected ﬁbre tracts, using an in-house written
MATLAB script. A detailed description can be found in the
Supplementary material. Brieﬂy, to reconstruct the streamlines
of the ﬁbre tracts, whole-brain tractography based on the
Table 1 Subject characteristics
Group Non-carriers
(n = 45)
Carriers
(n = 64)
Gender, male/female (%) 24 (53) / 21 (47) 28 (44) / 36 (56)
Age, years, mean  SD 38.8  10.6 38.0  11.2
EYO, years, mean  SD –5.8  11.3 –8.4  11.6
Education, years
(mean  SD)
15.1  2.0 14.0  3.6*
APOE "4, NC/C (%) 30 (67) / 15 (33) 50 (78) / 14 (22)
Symptomatic, A/S (%) 44 (98) / 1 (2) 32 (52) / 31 (48)a
A = asymptomatic; C = carrier; NC = non-carrier; S = symptomatic.
*P5 0.05 (two-sample t-test).
aOne carrier had no clinical dementia rating available.
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Johns Hopkins University DTI template was performed.
Inclusion and exclusion regions of interest were placed at
anatomical landmarks according to a previously established
protocol, in order to extract the ﬁbre tracts of the atlas
(Wakana et al., 2007). To determine the projection of the
ﬁbres into grey matter, the direction of ﬁbre projection was
estimated based on a series of tangents estimated at regularly
spaced points within the terminal section of each ﬁbre
(Supplementary Fig. 1). Based on the thus estimated direction
of the terminal section of a ﬁbre, the ﬁbre was projected into
the grey matter mask that was superimposed onto the DTI
image in MNI space. The grey matter voxels surrounding the
projected ﬁbre deﬁned the grey matter projections zone. The
grey matter projection zone masks were superimposed onto
each subject’s spatially normalized grey matter image (in
MNI space) for extraction of the grey matter volume for
each tract and subject.
Global white matter changes
In addition to regional mean diffusivity changes, we analysed
global mean diffusivity changes, using the DTI-based bio-
marker ‘peak-width of skeletonized mean diffusivity’
(PSMD), which was recently developed and cross-validated
(Baykara et al., 2016). Speciﬁcally, in the ﬁrst step, the inten-
sity distribution of mean diffusivity values within the TBSS-
derived white matter skeleton was plotted. Subsequently, the
PSMD was computed as the difference between the 5th and
95th percentile of the skeletonized mean diffusivity histogram
(within the custom white matter mask). A higher PSMD value
indicates a higher dispersion of mean diffusivity values, indi-
cative of local mean diffusivity alterations within the white
matter.
CSF biomarker assessment
Amyloid-b1-42, total tau and hyperphosphorylated tau (P-tau181)
were analysed by multiplexed Luminex-based immunoassay
(INNO-BIA AlzBio3, Fujirebio). CSF soluble TREM2 was mea-
sured by an ELISA previously established based on the MSD
Platform (Kleinberger et al., 2014; Suarez-Calvet et al., 2016a).
MRI and amyloid PET markers
For precuneus Pittsburgh compound B (PIB)-PET, we applied a
FreeSurfer-based extraction of the binding potential, that was
partial-volume corrected based on a regional spread-function
approach (Rousset et al., 1998). Of 21 carriers and 24 non-
carriers in whom PIB-PET was available, 16 carriers were
amyloid positive (mean cortical binding potential4 0.18)
(Mintun et al., 2006; Gordon et al., 2016) and none of the
non-carriers.
For hippocampus volume, FreeSurfer-based segmentation
was used. Correction for total intracranial volume was done
using a regression approach as previously described (Jack
et al., 1989; Benzinger et al., 2013).
Statistical analyses
The mean diffusivity values were the primary measure of white
matter integrity. Other commonly used DTI indices include
fractional anisotropy, radial diffusivity and axial diffusivity,
which were included as secondary measures for exploratory
reasons.
Voxel-wise analysis using TBSS
For the analysis of differences in mean diffusivity between carriers
and non-carriers during the course of autosomal-dominant
Alzheimer’s disease, we tested linear regression models with
mean diffusivity as the dependent variable and the interaction
EYO  mutation status, EYO, mutation status, sex and years of
education as predictors. Statistical signiﬁcance was determined
through non-parametric tests (500 permutations), as implemented
in the toolbox Randomise of FSL (Winkler et al., 2014).
Threshold-free cluster enhancement (TFCE) with a signiﬁcance
level of P = 0.05 (family-wise error corrected) was applied (Smith
and Nichols, 2009). Since the hippocampus cingulum bundle is
only a thin band of white matter, and thus a cluster-based signiﬁ-
cance threshold is less sensitive, we relaxed the signiﬁcance criter-
ion to P50.01 (voxel-based uncorrected) for that tract. The same
analyses were run for fractional anisotropy, radial diffusivity and
axial diffusivity as dependent variables. To determine common
spatial patterns of changes for mean diffusivity, fractional anisot-
ropy, radial diffusivity and axial diffusivity, we binarized each of
the TBSS results at the signiﬁcant threshold level and computed
the intersection of the thresholded statistical maps. In addition, we
computed voxel-level group differences in mean diffusivity between
symptomatic carriers (clinical dementia rating40), asymptomatic
carriers (clinical dementia rating = 0) and non-carriers, using the
same covariates as for the previous analyses.
Next, we illustrated the TBSS-derived interaction effects on
mean diffusivity. Since this is not possible for each voxel, we
generated interaction plots for each major ﬁbre tract in order
to cover regional variations. Speciﬁcally, we calculated the
average mean diffusivity across all voxels showing signiﬁcant
interaction effects for each ﬁbre tract region of interest. To this
end, the Johns Hopkins University ﬁbre tract atlas (Hua et al.,
2008) in MNI space was superimposed onto the thresholded
TBSS map and the average mean diffusivity within the masks’
intersection was computed.
PSMD marker of global white matter change
Lastly, we assessed the interaction effect EYO  mutation
status on global mean diffusivity changes using the previously
proposed PSMD, a marker of white matter changes. Statistical
analyses on PSMD were done in an analogous fashion as for
the voxel-based mean diffusivity map.
Assessing the influence of white matter
hyperintensity on mean diffusivity alterations
To map the spatial distribution of WMH in carriers and non-
carriers, we computed the voxel-wise occurrence of WMH as
the number of participants exhibiting a WMH in that voxel
was divided by the total number of participants in the group
(see Supplementary material for further details).
Temporal ordering of mean diffusivity changes
To assess how early abnormal mean diffusivity changes occur,
we studied the trajectories of mean diffusivity across EYO for
each ﬁbre tract, using the same statistical method described
previously (Suarez-Calvet et al., 2016a). Speciﬁcally, we used
the average mean diffusivity values for each ﬁbre tract region
of interest described above (see ‘Voxel-wise analysis using
TBSS’ section above) as the dependent variable to estimate
the coefﬁcient for the interaction effect (EYO  mutation
status) for each tract. Using robust linear regression analysis
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with M-estimation (implemented in the R-package MASS)
(Venables and Ripley, 2002), we tested predictors including
mutation status, EYO, EYO  mutation status, sex and years
of education. Prior to the regression analyses, outliers were
removed separately in carriers and non-carriers, using the
Tukey criterion: average mean diffusivity41.5  IQR4
median. At most, ﬁve data points (i.e. participants) were
removed for any given tract. Based on the thus estimated re-
gression coefﬁcients, we computed point estimates of tract-
based average mean diffusivity values and PSMD for each
group and EYO (ranging from EYO = 25 to EYO = +10,
in 5-EYO steps). For each EYO value we computed 95% con-
ﬁdence intervals (CI) of the difference in the point estimates
between carriers and non-carriers at each EYO step. The
group differences in mean diffusivity and PSMD were con-
sidered statistically signiﬁcant at a particular EYO if the
95% CI of the group difference did not include zero.
Mean diffusivity changes within the biomarker
cascade model
We modelled changes in PSMD and forceps major, which
showed the earliest changes in mean diffusivity, as a function
of EYO. In addition, standard biomarkers included (i) PIB-PET
within the precuneus and CSF amyloid-b1-42 as biomarkers of
amyloid deposition; (ii) CSF total tau as a biomarker of neu-
rodegeneration; (iii) hippocampal volume as a marker of grey
matter atrophy (Benzinger et al., 2013; Fagan et al., 2014);
and (iv) CSF-soluble TREM2 as marker of microglial activa-
tion (Suarez-Calvet et al., 2016a). The trajectories for each
measure were modelled according to the same statistical meth-
ods as described previously (Bateman et al., 2012; Suarez-
Calvet et al., 2016a). Speciﬁcally, starting with linear terms,
we successively added higher order terms to increase the over-
all model ﬁt, using the Akaike information criterion as a pen-
alty function and stopping criterion. For the estimation of the
biomarker curves, we applied the thus estimated regression
equations, rather than locally weighted scatter plot smoothing
(LOESS) (Bateman et al., 2012), to obtain an exact illustration
of the estimated regression coefﬁcients. This approach resulted
in more linear biomarker curves compared to those reported
previously (Bateman et al., 2012).
Relationship between mean diffusivity and core
autosomal-dominant Alzheimer’s disease
biomarkers
We computed robust linear regressions with PSMD as the
main outcome and each of the three CSF biomarkers (amyl-
oid-b1-42, total tau, P-tau181 and soluble TREM2) as well as
PIB-PET uptake in the precuneus as the main predictors within
the carrier group.
In addition, we computed robust linear regressions with
tract-speciﬁc mean diffusivity as main predictor and grey
matter volume at the projection zone of the tract as main
outcome variable, to assess associations between white
matter alterations and changes in the grey matter. All analyses
included sex and education as covariates.
Data availability
Both raw and processed data that support the ﬁndings of the
current study will be made available upon request to the
corresponding author and the DIAN committee in order to
ensure that the privacy of the DIAN participants is protected.
Results
Subject characteristics
Subject characteristics are presented in Table 1. Carriers were
less educated than non-carriers [t(93.8) = 2.03, P = 0.045],
but the groups did not differ in terms of age, sex distribution
and APOE "4 genotype distribution.
Mapping group differences in mean
diffusivity across estimated years
from symptom onset
We found signiﬁcant interactions of EYO by mutation status
on mean diffusivity predominantly in posterior parietal and
medial frontal regions of the white matter (Fig. 1, peak coord-
inates in Table 2), indicating a faster increase of mean diffu-
sivity in carriers compared to non-carriers. No interactions in
the opposite direction were observed. For global white matter
differences in mean diffusivity, assessed by the PSMD bio-
marker, the interaction effect EYO  mutation status was
B(standard error, SE) = 1.7(0.6)  106, P5 0.001, indicating
a faster progression in PSMD with EYO for carriers.
Regression plots of the TBSS-assessed interaction effect
EYO  mutation status on mean diffusivity are illustrated at
the ﬁbre tract level in Fig. 2. These results on mean diffusivity
were largely consistent with those found for alternate DTI in-
dices including fractional anisotropy, radial diffusivity and
axial diffusivity (Supplementary material, Supplementary Figs
3–6 and Supplementary Tables 3–5).
Mean diffusivity alterations in
symptomatic and non-symptomatic
carrier groups
The symptomatic carrier group (clinical dementia rating4 0,
n = 31) showed increased mean diffusivity compared to non-
carriers (n = 32, after matching the EYO range) primarily in
regions of the posterior white matter, similar to the TBSS
analysis of the interaction EYO  mutation status
(Supplementary Fig. 2A and Supplementary Table 1). No
group differences in the opposite direction were observed.
The results of the regression analysis of the interaction
EYO  mutation status within the asymptomatic carrier
group and all non-carriers was not signiﬁcant, probably
due to a lack power of this smaller sample. When compared
with asymptomatic carriers (clinical dementia rating = 0),
symptomatic carriers showed increased mean diffusivity in
predominantly parietal regions (Supplementary Fig. 2B and
Supplementary Table 2).
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Influence of white matter
hyperintensity on mean
diffusivity changes
Probability mapping of WMHs showed that WMHs were
mostly distributed around the ventricles and in posterior
parts of the white matter, which was more pronounced in
the carriers compared to the non-carriers (Supplementary Fig.
7). To assess whether the occurrence of WMHs account for
the observed alterations in mean diffusivity, we tested the inter-
action EYO  mutation status on the mean mean diffusivity
values for each ﬁbre tract, where the mean diffusivity was
averaged either within the WMH or the normal-appearing
part of a tract. For each tract, the regression analyses yielded
virtually the same interaction effect of EYO  mutation status
on mean diffusivity regardless of whether mean diffusivity
values were averaged within or outside WMH areas of a par-
ticular tract (Supplementary Fig. 8). This indicates that the oc-
currence of mean diffusivity changes found in carriers were not
exclusively dependent on the presence of WMHs.
In addition to WMHs, microbleeds and cortical siderosis
was assessed. Only three subjects showed any microbleeds
Figure 1 Abnormal mean diffusivity changes as a function of EYO. P-value map of the statistically significant voxel-wise interactions of
EYO  mutation status on mean diffusivity (red-yellow) superimposed on the white matter skeleton (blue, axial view), FWE-corrected at P = 0.05.
Table 2 Fibre tract and MNI coordinates of peak T-statistic values of the interaction of EYO  mutation status on
mean diffusivity
Cluster Tract Reference x y z T-value
1 Forceps major Occipital lobe 24 79 1 4.73
2 Superior longitudinal fasciculus R Frontal lobe 30 16 41 4.47
3 Inferior longitudinal fasciculus R Temporal lobe 43 23 16 3.81
4 Superior longitudinal fasciculus L Temporal lobe 50 36 9 3.69
5 Forceps minor Frontal lobe 21 24 33 2.99
6 Inferior fronto-occipital fasciculus L Frontal lobe 22 22 5 3.23
7 Superior longitudinal fasciculus L Caudate 27 0 26 3.61
8 Superior longitudinal fasciculus L Temporal lobe 55 33 10 3.39
L = left; R = right. The MNI coordinates are in millimetres.
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(n = 1, 4 or 100 in the cortex, respectively). Cortical side-
rosis was detected in the subject who had one microbleed.
Note that the subjects with one and 100 microbleeds had
been excluded from all DTI analyses due to intracerebral
haemorrhage (in the case with one microbleed) and sus-
pected cerebral amyloid angiopathy (in the case of 100
microbleeds). Thus, microbleeds were unlikely to have
any inﬂuence on the current analysis.
Temporal ordering of tract-based
mean diffusivity differences
At the tract level, mean diffusivity increases became signiﬁ-
cant ﬁrst at EYO = (10, 5) for the forceps major and
forceps minor, respectively (Fig. 3). Subsequently, mean dif-
fusivity differences occurred at EYO = (5, 0). The inferior
fronto-occipital fasciculus, the anterior thalamic radiation
and the inferior and superior longitudinal fasciculi. The
global mean diffusivity marker PSMD became abnormal
in the interval EYO = (10, 5).
Figure 4 shows the estimated trajectories of changes in
the forceps major, PSMD, and standard biomarkers of
Alzheimer’s disease. Alterations of mean diffusivity in the
forceps major and the PSMD became signiﬁcant at
EYO = (–10, –5). Thus, changes in mean diffusivity ap-
peared after changes in amyloid deposition [CSF amyloid-
b1-42: EYO = (15, 10), PIB-PET: EYO = (20, 15)], and
tau [CSF total tau: EYO = (20, 15)]. The white matter
changes were concurrent with changes in microglial activa-
tion [CSF soluble TREM2: EYO = (10, 5)] and preceded
changes in grey matter atrophy [hippocampal volume:
EYO = (5, 0)].
Relationship between mean
diffusivity and biomarkers of
Alzheimer’s disease pathology
and microglial activation
To reduce the number of tests, we assessed the relationship
between biomarkers for Alzheimer’s disease and mean dif-
fusivity for the global marker PSMD.
Higher PSMD was associated with lower CSF amyloid-b1-42
[B(SE) =0.47(0.12), P5 0.001; Fig. 5A] and increased PIB-
PET binding potential [B(SE) = 0.68(0.15), P5 0.001; Fig.
5B]. In addition, higher PSMD was associated with higher
levels of CSF total tau [B(SE) = 0.38(0.12), P = 0.003; Fig.
5C], P-tau [B(SE) = 0.41 (0.12), P5 0.001], and higher
levels of the microglia biomarker CSF soluble TREM2,
[B(SE) = 0.29(0.14), P = 0.042; Fig. 5D]. For P-tau181 the re-
sults were almost indistinguishable from those for total tau
due to the high correlation between the two biomarkers
(plot not shown).
To test the region-speciﬁc association between CSF bio-
markers and mean diffusivity, we ﬁrst conducted a voxel-
based regression of mean diffusivity onto TREM2 in the
mutation carriers. We found signiﬁcant associations between
mean diffusivity and CSF soluble TREM2 that were pre-
dominantly located in temporal and parietal regions of the
white matter, including ﬁbre tracts such as the forceps major
Figure 2 Tract-specific mean diffusivity changes as a function of EYO. Regression plots for the interaction EYO  mutation status on
mean diffusivity are shown for each fibre tract and the PSMD value. The regression lines including the 95% CIs (shaded bands) for mutation
carriers (red) and non-carriers (blue) as a function of EYO are displayed.
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and minor among other tracts (Fig. 6A, peak coordinates in
Supplementary Table 6). Since recent studies suggested that
tau is associated with neurodegeneration and white matter
diffusivity particularly at high levels of amyloid deposition
(Desikan et al., 2011; Jacobs et al., 2018), we tested the
interaction between CSF amyloid-b1-42  total tau on mean
diffusivity. Results are shown in Fig. 6B (peak coordinates in
Supplementary Table 7).
Relationship between fibre-tract
specific mean diffusivity and grey
matter volume in the tracts’
projection zones
Fibre tract degeneration has been associated with reduced
grey matter volume in connected brain regions (Duering
et al., 2012). Here, we found that higher tract-speciﬁc
mean diffusivity was associated with lower grey matter
volume in the projection zones of all tracts except the hip-
pocampal cingulum bundle (for each tract FDR-corrected
P-value5 0.01; Supplementary Fig. 9).
Discussion
The major ﬁnding of the current study was the region-spe-
ciﬁc increase in mean diffusivity that emerged about 10
years before the estimated onset of dementia symptoms.
These ﬁbre tract alterations were not restricted to WMH
areas, suggesting that subtle changes in the normal-
appearing white matter were already present years before
the onset of dementia symptoms. Higher mean diffusivity
was associated with lower CSF amyloid-b1-42, higher CSF
tau and CSF soluble TREM2, suggesting that early white
matter alterations were associated with primary
Alzheimer’s disease pathology and microglia activity.
Our current ﬁndings provide novel insights to clarify the
question of whether white matter alterations precede the
onset of dementia symptoms and if so which ﬁbre tracts
are affected ﬁrst in the course of Alzheimer’s disease
(Acosta-Cabronero and Nestor, 2014; Teipel et al., 2015).
Our results revealed an abnormal increase in mean
Figure 3 Time of first detectable changes in mean diffusivity. Ninety-five per cent confidence intervals of the estimated mean diffusivity
and PSMD differences between mutation carriers and non-carriers at each EYO are shown. Red indicates the earliest time point of abnormal
mean diffusivity values for a particular tract.
Figure 4 Trajectories of white matter alterations and
biomarkers across EYO. Trajectories of alterations in mean dif-
fusivity in the forceps major, and PSMD (green) along with those of
core Alzheimer’s disease biomarkers and CSF soluble TREM2.
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diffusivity in the forceps major (which projects into the
posterior parietal and occipital cortex) a decade before
the onset of dementia symptoms, with the forceps minor
(which projects into the medial and lateral frontal cortex)
and long-ranging projection ﬁbres such as the inferior
fronto-occipital fasciculus all showing abnormal mean dif-
fusivity several years before the expected onset of dementia
symptoms. Anterior and posterior callosal ﬁbres and ﬁbres
such as the inferior-fronto-occipital fasciculus provide
major connections within the anterior and posterior com-
ponents of the default mode network regions (van den
Heuvel et al., 2009), a functional network showing reduced
connectivity in early-stage Alzheimer’s disease (Sorg et al.,
2007; Chhatwal et al., 2013). Although any correlational
data preclude a causative conclusion, our ﬁndings support
the possibility that callosal white matter degeneration con-
tribute to functional disruption of functional networks such
as the default mode network (Chhatwal et al., 2013;
Mueller and Weiner, 2017; Taylor et al., 2017). The hip-
pocampal cingulum bundle showed alterations only after
the expected onset of symptom. However, the cingulum
bundle is only a thin white matter tract, which may
render a region of interest approach less sensitive to
detect diffusion alterations in that tract. It is important to
note that current ﬁndings on DTI assessed white matter
differences show where mean diffusivity alterations can be
ﬁrst detected, but not necessarily where they ﬁrst occur.
The sensitivity to detect white matter alterations via DTI
Figure 5 Global white matter alteration associated with Alzheimer’s disease biomarkers and CSF soluble TREM2. Regression
plots for PSMD versus CSF amyloid-b1-42 (A), precuneus PIB-PET (B), CSF total tau (C) and CSF-soluble TREM2 (D) in the carrier group. The
shaded areas correspond to the 95% CIs of the regression lines. BP = binding potential; IS = internal standard.
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Figure 6 Association between CSF markers and regional mean diffusivity in the carriers. Top: Map of P-values for the association
between higher CSF soluble TREM2 and higher mean diffusivity (red–yellow) superimposed on the white matter skeleton (blue), FWE-corrected
at P = 0.05. Bottom: Map of P-values for the interaction effect of CSF amyloid-b1-42 by total tau on mean diffusivity. MD = mean diffusivity.
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may differ between ﬁbre tracts. In addition to the regional
change, we found abnormally increased levels of the PSMD
marker of global white matter changes years before esti-
mated symptom onset early. The PSMD is fully automated
index is sensitive to regionally heterogeneous abnormal
mean diffusivity values (Baykara et al., 2016). The current
ﬁndings suggest that PSMD was sensitive to the earliest
white matter changes observed in the callosal ﬁbres, and
may thus be a candidate marker for early white matter
changes such as occurring in Alzheimer’s disease.
The current results are consistent with previous studies
on presumed preclinical Alzheimer’s disease, reporting
decreased ﬁbre tract integrity within the posterior parietal
white matter and medial temporal white matter to be asso-
ciated with imminent conversion from asymptomatic cog-
nitive status to mild cognitive impairment within 2 years
(Zhuang et al., 2012) or with the presence of both abnor-
mal levels of CSF amyloid and neuroinjury markers (FDG-
PET hypometabolism or CSF tau) (Bendlin et al., 2012;
Kantarci et al., 2014). In a similar vein, a combined ante-
mortem DTI and post-mortem histochemical analysis in
brains from cognitively normal participants found amyloid
and tau pathology to be associated with ante-mortem DTI
alterations selectively in the medial temporal and parietal
white matter (Kantarci et al., 2017). In contrast, increased
amyloid deposition alone was not found to be associated
with DTI changes at the preclinical stage. The current ﬁnd-
ings on the estimated trajectories of DTI and biomarkers of
Alzheimer’s disease pathology extend these previous results
suggesting that subsequent to the elevation of amyloid and
tau pathology, alterations in frontal and parietal white
matter regions start to develop a decade before dementia
onset.
WMHs are considered an MRI detectable marker of
white matter changes due to microvascular pathology,
and are increased in autosomal-dominant Alzheimer’s dis-
ease (Lee et al., 2016). Our DTI-based results demonstrated
an increase in mean diffusivity with disease progression
both inside and outside areas of WMH. Importantly, this
ﬁnding does not dispute the possible contribution of amyl-
oid-b-related small vessel changes to the observed white
matter alterations. WMHs manifest as regions of increased
diffusivity in DTI and likely reﬂect the tip of the iceberg of
underlying microstructural white matter changes: subtle
white matter degeneration, detectable at ﬁrst only with
DTI, may gradually increase before becoming visible as
macroscopic WMHs (Pelletier et al., 2015), which in turn
give rise to lacunes (Duering et al., 2013). Thus, the differ-
ence of microstructural white matter degeneration inside
versus outside of WMHs is likely of quantitative rather
than qualitative nature, and the same potentially amyloid
related pathomechanisms may underlie these white matter
alterations.
Primary Alzheimer’s disease pathology may have a direct
role in inducing ﬁbre tract degeneration. Converging evidence
suggests that amyloid-b and tau-related pathology contribute
to chronic hypoperfusion of white matter tissue (Iadecola
et al., 1999; Park et al., 2008). Deposition of amyloid-b
within microvessels is highly frequent in patients with
Alzheimer’s disease dementia (Kalaria, 2016) and associated
with reduced blood ﬂow in transgenic mouse models (Han
et al., 2008; Saito et al., 2017) and humans (Chung et al.,
2009; Dumas et al., 2012). Amyloid-induced vascular con-
striction, increased vascular resistance, and degeneration of
pericytes may further contribute to hypoperfusion (Kisler
et al., 2017; Yew et al., 2017). Thus, increased amyloid path-
ology may contribute to microvascular damage leading to
white matter degeneration (for review see Sachdev et al.,
2013). It should be noted that although white matter changes
were detected subsequent to amyloid and tau pathology in
the current study, it is still possible that age-related cerebro-
vascular pathology may precede primary Alzheimer’s disease
pathology (Iturria-Medina et al., 2016) and contribute to
white matter changes to a stronger degree in subjects with
sporadic Alzheimer’s disease compared to the relatively
young subjects with autosomal-dominant Alzheimer’s disease.
Another major open question is the role of microglial
activation in the decline of brain integrity in Alzheimer’s
disease. Rare partial loss-of-function mutations in the
TREM2 gene are associated with an increase in the risk
of Alzheimer’s disease dementia, comparable to that asso-
ciated with the APOE "4 allele (Guerreiro et al., 2013;
Jonsson et al., 2013). The protein TREM2 is a receptor
primarily expressed in the brain by microglia. TREM2 mu-
tations may be associated with a loss of function affecting
microglial chemotaxis, migration, survival, and binding of
phospholipids and APOE (Kleinberger et al., 2014, 2017;
Atagi et al., 2015; Bailey et al., 2015; Wang et al., 2015;
Yeh et al., 2016; Mazaheri et al., 2017; Ulland et al.,
2017). TREM2 is actively shed by ADAM10 and
ADAM17 (Schlepckow et al., 2017) and released into the
CSF (Kleinberger et al., 2014). We have previously shown
CSF levels of soluble TREM2 to be increased in the pro-
dromal at-risk state of Alzheimer’s disease (Suarez-Calvet
et al., 2016b), preceding the estimated age of onset of de-
mentia symptoms by 5–10 years as estimated in auto-
somal-dominant Alzheimer’s disease (Suarez-Calvet et al.,
2016a). Although it remains largely unclear which ligands
bind to the TREM2 receptor, recent in vivo experiments in
mice suggest that sphingomyelin stemming from damaged
myelin (Capodivento et al., 2017) binds to the TREM2
receptor, entailing the activation of microglia (Wang
et al., 2015). Thus, in Alzheimer’s disease higher ﬁbre
tract damage may result in increased number of microglia
and/or higher microglia activity via the TREM2 receptor.
Several caveats should be considered when interpreting
the current ﬁndings. First, as already mentioned above,
the generalizability of the ﬁndings from autosomal-domin-
ant Alzheimer’s disease to sporadic late-onset Alzheimer’s
disease remains to be tested. Since in autosomal-dominant
Alzheimer’s disease, the genetically caused increase in amyl-
oid accumulation may begin already in the third or fourth
decade of life, any age-related changes such as vascular
pathology that may impact on white matter integrity are
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unlikely to be detected in autosomal-dominant Alzheimer’s
disease, but may still exist in late-onset Alzheimer’s disease.
Second, the current study cannot preclude that white
matter alterations may have been due to Wallerian degen-
eration secondary to grey matter atrophy. However, previ-
ous neuroimaging as well as post-mortem brain studies
have observed white matter alterations in the presence of
minimal or only weak grey matter atrophy (de la Monte,
1989; Zhuang et al., 2012), suggesting that in principle
white matter alterations in Alzheimer’s disease are not de-
pendent on grey matter atrophy. Interestingly, a recent lon-
gitudinal study in subjects characterized by amyloid and
tau PET suggests that ﬁbre tract alterations may be condu-
cive to tau spreading and thus precede grey matter alter-
ations in the projection zones of a tract (Jacobs et al.,
2018). The current results encourage future longitudinal
studies to assess the role of successive white matter alter-
ations in the progressive expansion of grey matter atrophy.
Third, mean diffusivity was the primary measure to
detect white matter alterations in the current study. Mean
diffusivity is only one among many possible DTI indices.
DTI indices may reﬂect partially different underlying white
matter changes (Alexander et al., 2007), although this is
still a matter of intense research (Jones et al., 2013). For
exploratory reasons, we also analysed fractional anisot-
ropy, radial diffusivity and axial diffusivity, which
showed a substantial spatial overlap particularly in regions
including forceps major, forceps minor and posterior par-
ietal part of the cingulum bundle. Consistent with previous
studies in mild cognitive impairment (O’Dwyer et al., 2012)
and Alzheimer’s disease dementia (Acosta-Cabronero et al.,
2010, 2012; Bosch et al., 2012), we observed an increase in
axial diffusivity, albeit in a spatially more restricted manner
when compared to that of the other DTI indices.
We caution that the behaviour of the DTI indices in the
human brain, which is characterized by a high density of
crossing ﬁbre that inﬂuence DTI measures (Jeurissen et al.,
2013), is only partially understood and remains speculative
(Jones et al., 2013). DTI alterations may stem from a var-
iety of tissue changes including altered crossing ﬁbres, per-
meability of the axonal membrane, inﬂammation, or
oedema (Jones et al., 2013). Furthermore, although TBSS
is a widely-used approach to analyse DTI, the method has
several limitations as previously described, such as suscep-
tibility to misregistration artefacts, crossing ﬁbres, and in-
accurate voxel-assignment between neighbouring ﬁbre
tracts during the skeletonization procedure (Zalesky,
2011; de Groot et al., 2013; Bach et al., 2014). In particu-
lar, long projecting ﬁbres, such as the cortico-spinal tract,
cross many other tracts. DTI alterations such as those
observed in the corticospinal tract in the current study
should be interpreted with caution, as the current TBSS
approach cannot be unambiguously attributed to that
tract, but potentially are because of alterations in crossing
ﬁbres such as the superior longitudinal fasciculus or corpus
callosum (Douaud et al., 2011; Teipel et al., 2014; Mito
et al., 2018). Also, spatial misregistration may occur
particularly in cases of strong mismatch between the tem-
plate image and the individual images, such as those ob-
tained from elderly subjects with Alzheimer’s disease
dementia (Keihaninejad et al., 2012). However, in the cur-
rent study the ﬁrst white matter changes were detected in
the mutation carriers a decade before symptoms onset, i.e.
when no substantial grey matter atrophy is yet present, and
at a relatively young age (mean 38 years), rendering it
unlikely that those DTI alterations were due to gross mis-
registration artefacts. Furthermore, to reduce the likelihood
of partial volume effects, we applied a conservative white
matter mask, excluding regions most prone to artefacts
such as the fornix. We note that more advanced DTI meas-
ures, such as neurite orientation dispersion and density
imaging (NODDI) (Zhang et al., 2012), bi-tensor free-
water imaging, or ﬁxel-based analysis (Mito et al., 2018)
based on multishell-DTI have started to address this prob-
lem and will be instrumental in disentangling the different
sources of white matter alterations in Alzheimer’s disease.
In conclusion, the current ﬁndings suggest that white
matter alterations start in circumscribed regions predomin-
antly in posterior parietal and medial prefrontal white
matter, preceding the onset of dementia symptoms by
more than a decade. These ﬁbre tract changes are an inte-
gral part of the Alzheimer’s disease pathological cascade.
The current ﬁndings encourage future studies to assess the
effect of white matter alteration on the cascading break-
down of functional brain networks in Alzheimer’s disease.
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